Literature DB >> 19871253

THE SPECIFIC POLYSACCHARIDE CONTENT OF PNEUMONIC LUNGS.

A W Frisch1, J T Tripp, C D Barrett, B E Pidgeon.   

Abstract

1. The specific polysaccharide content of pneumonic lungs in Type III pneumonia was 60 times greater than in Type I, II, VII, and VIII cases. 2. The highest values were obtained from gray hepatized lobes, but the red hepatized and edematous areas also contained large quantities of S. 3. Comparable yields of polysaccharide were recovered from the sputa and lungs of fatal cases. 4. Preliminary peptic digest of lung exudates increased the S yields. 5. The data support the hypothesis that the outcome in Type III pneumonia is related to the ability of the pneumococci to produce capsular polysaccharide.

Entities:  

Year:  1942        PMID: 19871253      PMCID: PMC2135280          DOI: 10.1084/jem.76.6.505

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  Viable Pneumococci and Pneumococcic Specific Soluble Substance in the Lungs from Cases of Lobar Pneumonia.

Authors:  R N Nye; A H Harris
Journal:  Am J Pathol       Date:  1937-09       Impact factor: 4.307

2.  THE SPECIFIC POLYSACCHARIDE CONTENT OF PNEUMONIC SPUTA.

Authors:  J T Tripp; A W Frisch; C D Barrett; B E Pidgeon
Journal:  J Exp Med       Date:  1942-12-01       Impact factor: 14.307

3.  THE ELABORATION OF SPECIFIC SOLUBLE SUBSTANCE BY PNEUMOCOCCUS DURING GROWTH.

Authors:  A R Dochez; O T Avery
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

  3 in total
  9 in total

1.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Authors:  Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  J Antimicrob Chemother       Date:  2012-11-20       Impact factor: 5.790

3.  Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.

Authors:  Joseph M Blondeau; Shantelle D Fitch
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

4.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  The pneumococcus and some men who came to Yale: the Dorothy M. Horstmann Lecture.

Authors:  R Austrian
Journal:  Yale J Biol Med       Date:  1993 Jul-Aug

6.  Host-parasite relationships in experimental pneumonia due to pneumococcus type III.

Authors:  W B WOOD; M R SMITH
Journal:  J Exp Med       Date:  1950-07-01       Impact factor: 14.307

7.  Localization of antigen in tissue cells; cellular distribution of pneumococcal polysaccharides types II and III in the mouse.

Authors:  M E KAPLAN; A H COONS; H W DEANE
Journal:  J Exp Med       Date:  1950-01-01       Impact factor: 14.307

8.  Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets?

Authors:  Glenn S Tillotson; Stephen H Zinner
Journal:  EBioMedicine       Date:  2015-06-12       Impact factor: 8.143

9.  In vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities.

Authors:  Joseph M Blondeau; Shantelle D Fitch
Journal:  Vet Dermatol       Date:  2020-02-06       Impact factor: 1.589

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.